| Ytd | 13.36% | |
| 1y | 13.36% |
| Open | 14.06 | Prev Close | 13.99 | Low | 13.94 | High | 14.86 | Mkt Cap | 1.84B |
| Vol | 903.37K | Avg Vol | 1.05M | EPS | -2.44 | P/E | N/A | Forward P/E | -6.29 |
| Beta | N/A | Short Ratio | 4.66 | Inst. Own | 77.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 15.51 | 200-d Avg | 14.15 | 1yr Est | 27.00 |
GENB News
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Generate Biomedicines (NASDAQ:GENB)
Generate Biomedicines (NASDAQ: GENB - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Ge
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation
Squarepoint Ops LLC bought a new position in Generate Biomedicines Inc (NASDAQ: GENB) during the und
Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conferen
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Generate Biomedicines (NASDAQ:GENB)
SOMERVILLE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Ge
Wall Street analysts updated ratings for top names. Workday target raised, Ulta Beauty & Genasys
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB)
Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular ses
Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors posit
Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors posit
Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(0.52) per share which beat the an
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advan
Generate Biomedicines had its IPO this past February. The company has had buy-in from Nvidia and Amg
The chipmaker has active interests in the healthcare market, including a partnership with Eli Lilly
US stock futures lower as Dow falls 100 points. Nike shares down 4% after Q4 results. Shutterstock,
Constellation Brands (NYSE: STZ) rose in pre-market trading after reporting strong Q1 earnings and r
Newly Constructed Phase 2 now 100% Leased Further Solidifies Innovation Park as Boston's Premier Adv
This biotechnology firm leverages machine learning to design novel protein therapeutics targeting un
SOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today ann
Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:GENB) with a Overweigh
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB)
Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(1.07) per share which missed the
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinic
Top Wall Street analysts changed outlook on top names. Check our analyst ratings page for upgrades,
Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrade
Guru Stock PicksKen Fisher has made the following transactions:Reduce in DEO by 23.8%Sold out in VSH
Ark Invest bought shares of MercadoLibre, Intellia Therapeutics, and Generate Biomedicines on Monday
One IPO and six SPACs came to market this past week, and one major issuer joined the pipeline as Feb